# myNEO Therapeutics: complete current reference > This file is generated from the same canonical FAQ data shown on myneotx.com. It contains 93 current questions and answers in US English, with links to relevant pages and publications. Last verified: 2026-08-17 Canonical website: https://www.myneotx.com/ ## Canonical facts - myNEO Therapeutics is an AI-driven biotechnology company headquartered at Ottergemsesteenweg 439, 9000 Ghent, Belgium. - myNEO was founded in Ghent in December 2018 by Cedric Bogaert, Jan Van Den Berghe, and Wim van Criekinge. - ImmunoEngine is myNEO's antigen discovery pipeline. It identifies tumor-specific antigens from whole-genome sequencing. - neoMS and neoIM are standalone algorithms for MHC presentation and immunogenicity prediction. They are used inside ImmunoEngine and in dedicated solution workflows, and are described at https://www.myneotx.com/platform/neoms and https://www.myneotx.com/platform/neoim. - mySHARED and myPATHOGEN use dedicated discovery workflows, with neoMS and neoIM used for candidate ranking where relevant. - Camyotopes are proprietary dark-genome tumor antigens and are described at https://www.myneotx.com/platform/camyotopes. - How this differs from mutation-list and binding-only pipelines is summarized at https://www.myneotx.com/how-we-differ. - Current FAQs are collected at https://www.myneotx.com/faq. - As of August 2026, MNE-C261 is in preclinical development, with clinical initiation targeted for Q4 2027. Program page: https://www.myneotx.com/assets/mne-c261 - Computational predictions prioritize and de-risk candidates but do not replace experimental validation. ## Product and solution index - [mySURFACE](https://www.myneotx.com/solutions/mysurface): Surface target discovery. Live application: https://www.mysurface.myneotx.com/ - [myADA](https://www.myneotx.com/solutions/myada): Anti-drug antibody risk prediction. Live application: https://myada.myneotx.com/ - [mySELF](https://www.myneotx.com/solutions/myself): Autoimmune disease target discovery. - [myINSIGHTS](https://www.myneotx.com/solutions/myinsights): Large-scale data analysis. - [myNEO](https://www.myneotx.com/solutions/myneo): Personalized neoantigen target discovery. Live application: https://www.neohub.myneotx.com/ - [mySHARED](https://www.myneotx.com/solutions/myshared): Shared MHC-bound target discovery. - [myPATHOGEN](https://www.myneotx.com/solutions/mypathogen): Infectious disease target discovery. - [myEPITOPE](https://www.myneotx.com/solutions/myepitope): Immunogenicity screening. - [myCONSTRUCT](https://www.myneotx.com/solutions/myconstruct): Amino acid construct optimization. - [myRNA](https://www.myneotx.com/solutions/myrna): Codon optimization. ## Contact - General inquiries and partnerships: info@myneotx.com - Careers and spontaneous applications: hr@myneotx.com - Privacy questions: dpo@myneotx.com - Legal questions: legal@myneotx.com - Contact page: https://www.myneotx.com/contact ## Complete FAQ reference ## Company overview Page: https://www.myneotx.com/ ### What is myNEO Therapeutics? myNEO Therapeutics is a Ghent-based, AI-driven biotechnology company for antigen discovery, neoantigen discovery, and immune-target design. Its [ImmunoEngine platform](https://www.myneotx.com/platform/immunoengine) and [modular solutions](https://www.myneotx.com/solutions) support vaccine, T-cell, biologics, and other immune-driven developers across antigen discovery, immunogenicity prediction, construct design, codon optimization, and translational data analysis. ### Who does myNEO Therapeutics work with? myNEO works with cancer vaccine developers, T-cell therapy developers, biologics and antibody developers, infectious disease vaccine groups, pharmaceutical companies, and academic research teams. Its [solutions](https://www.myneotx.com/solutions) support target discovery and prioritization, product design, immunogenicity de-risking, and large-scale translational data analysis across therapeutic modalities and disease areas. ### What is ImmunoEngine? [ImmunoEngine](https://www.myneotx.com/platform/immunoengine) is myNEO's antigen discovery pipeline. It identifies tumor-specific antigens from whole-genome sequencing, including camyotope dark-genome targets, predicts MHC presentation with [neoMS](https://www.myneotx.com/platform/neoms), scores immunogenicity with [neoIM](https://www.myneotx.com/platform/neoim), and ranks the resulting candidates. ### What is antigen discovery? Antigen discovery identifies which proteins or peptides the immune system can recognize. At myNEO, [ImmunoEngine](https://www.myneotx.com/platform/immunoengine) performs antigen discovery and neoantigen discovery from whole-genome data, then ranks candidates for vaccine, T-cell, and other immune-driven programs. ### Does myNEO do neoantigen discovery? Yes. [ImmunoEngine](https://www.myneotx.com/platform/immunoengine) performs antigen discovery and neoantigen discovery for personalized and shared immunotherapy programs. Dedicated solutions then cover surface targets, immunogenicity, construct design, and analysis. ### What problems does myNEO help solve? myNEO addresses the target-selection bottleneck in immunotherapy: most computationally predicted targets never trigger a T-cell response. Its solutions identify which epitopes are presented and immunogenic, find shared and surface targets, [reduce anti-drug antibody risk](https://www.myneotx.com/solutions/myada), and design [multi-epitope constructs](https://www.myneotx.com/solutions/myconstruct) and [mRNA sequences](https://www.myneotx.com/solutions/myrna). ### Can myNEO solutions be used independently? Yes. Each [solution](https://www.myneotx.com/solutions) can be used independently for a defined task or project, or multiple solutions can be combined into an integrated workflow based on the needs of the customer. ## Company history and location Page: https://www.myneotx.com/about-us ### Where is myNEO Therapeutics located? myNEO Therapeutics is headquartered at [Ottergemsesteenweg 439, 9000 Ghent, Belgium](https://www.myneotx.com/contact). ### When was myNEO Therapeutics founded? myNEO was founded in Ghent, Belgium, in December 2018 by Cedric Bogaert, Jan Van Den Berghe, and Wim van Criekinge as the third company incorporated by Novalis Biotech Incubation. It was established to identify, explore, and validate targets for personalized cancer immunotherapy, forming the technological basis for the [ImmunoEngine platform](https://www.myneotx.com/platform/immunoengine). ### Is myNEO's technology supported by peer-reviewed publications? Yes. The neoMS and neoIM algorithms are described in [Mill et al., bioRxiv 2022](https://www.myneotx.com/publication/mill-neoms-mhc-epitope-presentation-2022), and [Pfitzer et al., Vaccines 2025;13(8):865](https://www.myneotx.com/publication/pfitzer-accelerating-neoantigen-discovery-2025), respectively. Two peer-reviewed articles provide broader context: [Lybaert et al., Trends Cancer 2023;9(6):503-519](https://www.myneotx.com/publication/lybaert-neoantigen-therapeutics-clinic-2023), and [Lybaert et al., Cancer Cell 2023;41(1):15-40](https://www.myneotx.com/publication/lybaert-challenges-neoantigen-therapeutics-2022). Additional [technology papers and whitepapers](https://www.myneotx.com/publications) cover myNEO solutions and research. ## ImmunoEngine and core algorithms Page: https://www.myneotx.com/platform ### What is ImmunoEngine? ImmunoEngine is myNEO's computational antigen discovery pipeline. It calls variants from whole-genome tumor and healthy sequencing data, including events beyond SNVs and indels such as fusions, neoisoforms, and dark-genome [camyotopes](https://www.myneotx.com/platform/camyotopes). It characterizes the patient's HLA type and tumor microenvironment, predicts MHC presentation with [neoMS](https://www.myneotx.com/platform/neoms), scores immunogenicity with [neoIM](https://www.myneotx.com/platform/neoim), and ranks the resulting targets. ### What is neoantigen discovery? Neoantigen discovery identifies tumor-specific antigens the immune system can recognize. [ImmunoEngine](https://www.myneotx.com/platform/immunoengine) performs neoantigen discovery from whole-genome tumor and healthy sequencing, then uses [neoMS](https://www.myneotx.com/platform/neoms) presentation prediction and [neoIM](https://www.myneotx.com/platform/neoim) immunogenicity prediction to rank candidates for vaccine, T-cell, and other immunotherapy programs. ### Why does ImmunoEngine use both DNA and RNA sequencing? myNEO uses DNA and RNA sequencing data from the tumor and DNA sequencing from matched healthy tissue. Comparing tumor and healthy DNA identifies alterations that are tumor-specific rather than inherited. Tumor RNA then shows which alterations are expressed, helping prioritize actionable targets for therapeutic development. ### What is neoMS? [neoMS](https://www.myneotx.com/platform/neoms) is myNEO's deep-learning MHC presentation prediction algorithm. Rather than modeling binding affinity alone, it models the full antigen-processing and presentation pathway. It is HLA-agnostic, enabling predictions for alleles not observed during training. Originally developed for MHC class I, neoMS now also covers class II. ### What is neoIM? [neoIM](https://www.myneotx.com/platform/neoim) is myNEO's machine-learning-based immunogenicity prediction algorithm. It estimates the probability that an epitope elicits a T-cell response. Candidate epitopes are ranked according to predicted CD8+ and CD4+ T-cell immunogenicity to support the selection of biologically relevant targets. ### How does ImmunoEngine prioritize neoantigens? ImmunoEngine scores both the genomic event and the peptide it produces. The event is assessed for prevalence, clonality, tumor specificity, and expression. The peptide is assessed for presentation likelihood and predicted immunogenicity. These factors are combined into a ranking used to select the final epitope set while accounting for immune-escape risk. ### Why does myNEO use whole-genome sequencing instead of exome sequencing? Whole-genome sequencing reveals tumor alterations that exome panels cannot detect, including gene fusions, transposable elements, neoisoforms, and translated non-coding regions. In tumors with low mutational burden, these [dark-genome events](https://www.myneotx.com/publication/more-to-genome-wgs-neoantigen-discovery) can provide actionable targets when exome-based discovery finds few candidates. Whole-genome sequencing also supports higher-confidence variant calling. ### What are the limitations of myNEO's computational predictions? myNEO's outputs are in-silico predictions that prioritize and de-risk candidates before laboratory work. They reduce the number of candidates and experiments required, but they do not replace experimental validation and do not guarantee presentation, immunogenicity, safety, or clinical efficacy. ## ImmunoEngine Page: https://www.myneotx.com/platform/immunoengine ### What is ImmunoEngine? ImmunoEngine is myNEO's computational antigen discovery pipeline. It calls variants from whole-genome tumor and healthy sequencing data, including events beyond SNVs and indels such as fusions, neoisoforms, and dark-genome [camyotopes](https://www.myneotx.com/platform/camyotopes). It characterizes the patient's HLA type and tumor microenvironment, predicts MHC presentation with [neoMS](https://www.myneotx.com/platform/neoms), scores immunogenicity with [neoIM](https://www.myneotx.com/platform/neoim), and ranks the resulting targets. ### What is neoantigen discovery? Neoantigen discovery identifies tumor-specific antigens the immune system can recognize. [ImmunoEngine](https://www.myneotx.com/platform/immunoengine) performs neoantigen discovery from whole-genome tumor and healthy sequencing, then uses [neoMS](https://www.myneotx.com/platform/neoms) presentation prediction and [neoIM](https://www.myneotx.com/platform/neoim) immunogenicity prediction to rank candidates for vaccine, T-cell, and other immunotherapy programs. ### Why does ImmunoEngine use both DNA and RNA sequencing? myNEO uses DNA and RNA sequencing data from the tumor and DNA sequencing from matched healthy tissue. Comparing tumor and healthy DNA identifies alterations that are tumor-specific rather than inherited. Tumor RNA then shows which alterations are expressed, helping prioritize actionable targets for therapeutic development. ### How does ImmunoEngine prioritize neoantigens? ImmunoEngine scores both the genomic event and the peptide it produces. The event is assessed for prevalence, clonality, tumor specificity, and expression. The peptide is assessed for presentation likelihood and predicted immunogenicity. These factors are combined into a ranking used to select the final epitope set while accounting for immune-escape risk. ### Why does myNEO use whole-genome sequencing instead of exome sequencing? Whole-genome sequencing reveals tumor alterations that exome panels cannot detect, including gene fusions, transposable elements, neoisoforms, and translated non-coding regions. In tumors with low mutational burden, these [dark-genome events](https://www.myneotx.com/publication/more-to-genome-wgs-neoantigen-discovery) can provide actionable targets when exome-based discovery finds few candidates. Whole-genome sequencing also supports higher-confidence variant calling. ### What are the limitations of myNEO's computational predictions? myNEO's outputs are in-silico predictions that prioritize and de-risk candidates before laboratory work. They reduce the number of candidates and experiments required, but they do not replace experimental validation and do not guarantee presentation, immunogenicity, safety, or clinical efficacy. ## neoMS Page: https://www.myneotx.com/platform/neoms ### What is neoMS? [neoMS](https://www.myneotx.com/publication/mill-neoms-mhc-epitope-presentation-2022) is myNEO's deep-learning MHC presentation prediction algorithm. Rather than modeling binding affinity alone, it models the full antigen-processing and presentation pathway, including proteasomal cleavage, TAP transport, MHC binding, and presentation. It is HLA-agnostic, enabling predictions for alleles not observed during training. Originally developed for MHC class I, neoMS now also covers class II. ### How is neoMS different from MHC-binding predictors? Most presentation tools score MHC binding affinity. Binding is only one step of antigen processing, and it is a poor proxy for whether a peptide actually reaches the cell surface. [neoMS](https://www.myneotx.com/publication/mill-neoms-mhc-epitope-presentation-2022) is trained on mass-spectrometry MHC ligandomic data and uses a transformer-based, sequence-to-sequence model so ranking reflects presentation, not binding alone. ### Where is neoMS used? neoMS is used inside [ImmunoEngine](https://www.myneotx.com/platform/immunoengine) to rank candidate antigens, and as a standalone algorithm in dedicated discovery workflows such as [mySHARED](https://www.myneotx.com/solutions/myshared) and [myPATHOGEN](https://www.myneotx.com/solutions/mypathogen). ## neoIM Page: https://www.myneotx.com/platform/neoim ### What is neoIM? neoIM is myNEO's machine-learning immunogenicity prediction algorithm. It estimates whether an epitope will elicit a T-cell response. Candidates are ranked by predicted CD8+ and CD4+ immunogenicity. In [published retrospective analyses](https://www.myneotx.com/publication/pfitzer-accelerating-neoantigen-discovery-2025), neoIM achieved up to 30% higher precision than existing predictors and identified up to 50% more clinically actionable neoantigens. ### Does neoIM cover MHC class I and class II? Yes. neoIM predicts immunogenicity in MHC class I and class II contexts, supporting CD8+ and CD4+ T-cell ranking for vaccine and T-cell programs, and lower-immunogenicity selection for biologics where relevant. ### Where is neoIM used? neoIM is used inside [ImmunoEngine](https://www.myneotx.com/platform/immunoengine) to rank candidate antigens, in [myEPITOPE](https://www.myneotx.com/solutions/myepitope) immunogenicity screening, and in [mySELF](https://www.myneotx.com/solutions/myself) for autoimmune target discovery. ## Camyotopes Page: https://www.myneotx.com/platform/camyotopes ### What are camyotopes™? Camyotopes™ are proprietary tumor epitopes derived from the [dark genome](https://www.myneotx.com/publication/camyotopes-novel-class-tumor-targets). Tumor-specific long non-coding RNAs, called camyoRNAs, contain small open reading frames that produce camyopeptides. These peptides are processed and presented on MHC class I, where CD8+ T cells can recognize them. myNEO is developing off-the-shelf camyotope-targeting immunotherapies. ### What makes camyotopes different from other shared tumor antigens? Camyotopes are not dependent on recurrent coding mutations, providing a broader candidate pool for multi-target approaches that may reduce immune-escape risk. Within a given indication, [current data](https://www.myneotx.com/publication/camyotopes-novel-class-tumor-targets) report camyoRNA population coverage of 60-95%, compared with 20-30% cited for conventional off-the-shelf vaccines. Camyotope-based designs provide an average of six to eight effective targets per patient. ### Have camyotopes been experimentally validated? Camyotope targets have been validated preclinically across multiple endpoints, including immunogenicity and tumor-killing potential, where they outperformed conventional shared antigens. myNEO is working toward initiation of a first Phase I/IIa trial of the lead program, [MNE-C261](https://www.myneotx.com/assets/mne-c261), by Q4 2027. ### Can camyotopes be combined with other antigen classes? Yes. Camyotopes can be used on their own or supplemented with other shared antigens, including targets from intron retention, transposable elements, and alternative splicing. In indications where shared targets are sparse, they can be combined with personalized neoantigens, and with other immunotherapies such as checkpoint inhibitors. ### Are camyotopes relevant across disease stages? In colorectal cancer samples, camyoRNA prevalence was similar across stages, indicating that camyotope-based therapeutics can be relevant for both early- and late-stage patients. Expression is often limited to a specific tissue or tumor type, which can help limit off-target effects when targets are selected carefully. ## Solutions and access Page: https://www.myneotx.com/solutions ### What does myNEO offer biologics developers? For antibody, bispecific, antibody-drug conjugate, and cell therapy programs, myNEO offers surface-target discovery with [mySURFACE](https://www.myneotx.com/solutions/mysurface), anti-drug antibody risk prediction with [myADA](https://www.myneotx.com/solutions/myada), self-antigen and tolerance analysis with [mySELF](https://www.myneotx.com/solutions/myself), and large-scale translational data analysis with [myINSIGHTS](https://www.myneotx.com/solutions/myinsights). ### What does myNEO offer cancer vaccine and T-cell therapy developers? myNEO supports [personalized neoantigen discovery](https://www.myneotx.com/solutions/myneo), [shared MHC-bound antigen discovery](https://www.myneotx.com/solutions/myshared), [infectious disease antigen discovery](https://www.myneotx.com/solutions/mypathogen), [immunogenicity screening](https://www.myneotx.com/solutions/myepitope), [multi-epitope construct design](https://www.myneotx.com/solutions/myconstruct), [mRNA codon optimization](https://www.myneotx.com/solutions/myrna), and [translational data analysis](https://www.myneotx.com/solutions/myinsights). ### How do customers access myNEO's platforms? myNEO delivers its live solutions as hosted web applications. [myADA](https://myada.myneotx.com/), [mySURFACE](https://www.mysurface.myneotx.com/), and [neoHUB](https://www.neohub.myneotx.com/) are available online. Access is tenant-based so each customer's data remains isolated, with sign-in through Amazon Cognito and multi-factor authentication. ### Can I request a demo of a myNEO platform? Yes. Demonstrations are available for the live [myADA](https://www.myneotx.com/solutions/myada), [mySURFACE](https://www.myneotx.com/solutions/mysurface), and [neoHUB](https://www.myneotx.com/solutions/myneo) platforms and can be requested from the relevant product page. ### In which countries does myNEO provide its platforms? There are no geographic restrictions on platform access. The platforms are hosted on AWS and delivered over the web, enabling myNEO to work with customers worldwide. Project-specific data-handling arrangements are agreed contractually. ### Does myNEO take on customized computational projects? Yes. myNEO builds [customized computational workflows](https://www.myneotx.com/solutions#customized) for biological, clinical, and translational questions. It also develops web-based environments that help teams explore and interpret complex datasets across studies, departments, and research programs. ### Can myNEO handle both construct design and codon optimization? Yes. [myCONSTRUCT](https://www.myneotx.com/solutions/myconstruct) optimizes epitope order and spacer choice at the amino-acid level to avoid immunogenic junctions. [myRNA](https://www.myneotx.com/solutions/myrna) optimizes the encoding nucleotide sequence for structural stability, codon usage, modified nucleotides, and project-specific constraints. The technologies are often combined but are also available separately. ## mySURFACE Page: https://www.myneotx.com/solutions/mysurface ### What is mySURFACE? mySURFACE is myNEO's surface-target discovery platform for biologics. It identifies and prioritizes individual transmembrane targets and target pairs by integrating large-scale cancer expression data with surface-protein prediction. Supporting evidence is consolidated in a hosted web application at [mysurface.myneotx.com](https://www.mysurface.myneotx.com/). ### Why is surface-target discovery a bottleneck for biologics? Surface proteins are among the richest target classes in oncology but remain underexploited. Approved oncology biologics collectively address only a small number of distinct surface targets. As multispecific formats grow, developers need both new targets and validated target combinations. ### What does mySURFACE evaluate for each candidate target? mySURFACE assesses tumor specificity across bulk and single-cell expression and normal tissue, structural accessibility including glycosylation and 3D structure, internalization and shedding behavior, co-expression and paired-target potential, and published evidence. Scores are tailored to ADC, T-cell engager, and blocking formats. ### Who is mySURFACE for? mySURFACE supports developers of antibodies, bispecifics, antibody-drug conjugates, and cell therapies who need differentiated, high-confidence surface targets or validated target combinations with broad population coverage and evidence on accessibility, internalization, and normal-tissue expression. ### What is the typical turnaround for mySURFACE? Large-scale patient-cohort analyses with mySURFACE have an average turnaround time of two to three months. Project timing depends on scope and data readiness. ## myADA Page: https://www.myneotx.com/solutions/myada ### What is myADA? myADA is myNEO's in-silico anti-drug antibody risk-assessment platform, available at [myada.myneotx.com](https://myada.myneotx.com/). It identifies MHC class II epitopes with the potential to induce CD4+ T-cell responses, maps immunogenicity hotspots across the sequence, and interprets these findings in the context of the biologic's mechanism of action to estimate clinical ADA risk. ### How does myADA help antibody development? myADA ranks candidates by predicted ADA risk, identifies immunogenicity hotspots for targeted re-engineering, profiles humanness and similarity to known antibodies, and estimates population-level impact across HLA backgrounds. These outputs support lead selection and sequence optimization before wet-lab work. ### What is myADA benchmarked against? Every candidate is scored against a reference database of more than 100 clinically tested antibodies with documented real-world anti-drug antibody outcomes, annotated from more than 3,000 clinical trial arms across over 750 trials. A candidate's score is reported as a percentile within that clinically anchored distribution. ### What is the turnaround time for myADA? ADA risk prediction with myADA has a turnaround time of one week. Required inputs and deliverables are confirmed for each project. ### Is scientific documentation available for myADA? Yes. The [myADA technology paper](https://www.myneotx.com/publication/myada-anti-drug-antibody-risk-prediction) describes the model, its clinical reference database, and its benchmarking results. The paper is also available through the [publications library](https://www.myneotx.com/publications). ## mySELF Page: https://www.myneotx.com/solutions/myself ### What is mySELF? mySELF applies myNEO's immunogenicity prediction to autoimmune disease. It ranks self-peptides by predicted CD8+ and CD4+ immunogenicity to identify likely disease drivers and performs region-level analysis across protein sequences to support tolerance-oriented, antigen-specific therapeutic design. ### What is the typical turnaround for mySELF? Large-scale patient-cohort analyses with mySELF have an average turnaround time of two to three months. ## myINSIGHTS Page: https://www.myneotx.com/solutions/myinsights ### What is myINSIGHTS? myINSIGHTS analyzes large immunogenomic datasets to support biomarker discovery, patient stratification, response prediction, and trial design. It integrates sequencing, clinical, and experimental data within a unified analytical framework. myNEO can also provide interactive web-based environments for exploring and communicating the results. ### What data types can myINSIGHTS analyze? myINSIGHTS works with omics and sequencing data, T-cell receptor sequencing, ELISpot, intracellular cytokine staining, MSD multiplex panels, flow cytometry, antibody titers, exhaustion and immuno-oncology marker panels, immunohistochemistry, immunophenotyping, NanoString, and circulating tumor DNA monitoring. ## myNEO Page: https://www.myneotx.com/solutions/myneo ### What is the myNEO personalized discovery workflow? The myNEO workflow discovers and prioritizes neoantigens for individual patients. Starting from tumor and matched healthy sequencing data, it analyzes variant expression and translation, predicts MHC class I and II presentation, scores CD4+ and CD8+ immunogenicity, and selects a prioritized neoantigen set for downstream product design. ### What input data does the personalized workflow need? Three inputs are required: whole-genome and RNA sequencing of the tumor, and whole-genome sequencing of a matched healthy sample, which is usually blood. ### How long does personalized neoantigen discovery take? The personalized myNEO workflow has a turnaround time of five business days, from receipt of sequencing data to the prioritized neoantigen selection. Downstream construct design with [myCONSTRUCT](https://www.myneotx.com/solutions/myconstruct) and codon optimization with [myRNA](https://www.myneotx.com/solutions/myrna) can be delivered within one day. ### What is neoHUB? neoHUB is the web-based reporting platform for the personalized myNEO workflow, available at [neohub.myneotx.com](https://www.neohub.myneotx.com/). It presents variant analysis, expression data, predicted presentation and immunogenicity, and the prioritized neoantigen set so clinicians and researchers can review and interpret the workflow output. ### Can personalized discovery continue into product design? Yes. Selected neoantigens can proceed to [myCONSTRUCT](https://www.myneotx.com/solutions/myconstruct) for multi-epitope construct design, followed by [myRNA](https://www.myneotx.com/solutions/myrna) for codon optimization of the encoding sequence, producing a synthesis-ready multi-epitope design. ## mySHARED Page: https://www.myneotx.com/solutions/myshared ### What is mySHARED? mySHARED applies dedicated cohort-level discovery pipelines to identify MHC-bound targets shared across a defined cancer population. Source-specific workflows generate candidates from SNVs, indels, and dark-genome antigens, including [camyotopes](https://www.myneotx.com/platform/camyotopes). [neoMS](https://www.myneotx.com/platform/neoms) and [neoIM](https://www.myneotx.com/platform/neoim) rank these candidates by predicted presentation and immunogenicity before antigen sets are prioritized for population coverage. ### What is the typical turnaround for mySHARED? Large-scale patient-cohort analyses with mySHARED have an average turnaround time of two to three months. Project timing depends on cohort scope and data readiness. ## myPATHOGEN Page: https://www.myneotx.com/solutions/mypathogen ### What is myPATHOGEN? myPATHOGEN is a dedicated computational workflow for infectious disease antigen discovery. It combines sequence-conservation analysis with [neoMS](https://www.myneotx.com/platform/neoms) presentation prediction, [neoIM](https://www.myneotx.com/platform/neoim) immunogenicity prediction, and population-coverage optimization. The workflow prioritizes CD4+ and CD8+ T-cell targets that remain conserved across viral, bacterial, and parasitic strains. ### What is the turnaround time for myPATHOGEN? The end-to-end myPATHOGEN workflow has a turnaround time of eight weeks. Required data and deliverables are confirmed for each project. ### Can myPATHOGEN feed into construct design? Yes. Selected myPATHOGEN targets can proceed to [myCONSTRUCT](https://www.myneotx.com/solutions/myconstruct) for multi-epitope construct design and [myRNA](https://www.myneotx.com/solutions/myrna) for codon optimization. ## myEPITOPE Page: https://www.myneotx.com/solutions/myepitope ### What is myEPITOPE? myEPITOPE is myNEO's immunogenicity screening service, built on the [neoIM algorithm](https://www.myneotx.com/platform/neoim). It estimates whether a peptide will elicit a T-cell response. It works in MHC class I and class II contexts, supporting higher immunogenicity for vaccines and lower immunogenicity for biologics. ### How much does myEPITOPE improve epitope selection? In retrospective analyses of two published Phase I personalized cancer vaccine trials, myEPITOPE increased the share of selected epitopes producing a detectable CD8+ T-cell response from 47% to 70% in a melanoma trial and from 57% to 72% in a pancreatic cancer trial. ### What is the turnaround time for myEPITOPE? Immunogenicity screening with myEPITOPE has a turnaround time of one week. ## myCONSTRUCT Page: https://www.myneotx.com/solutions/myconstruct ### What is myCONSTRUCT? myCONSTRUCT supports the rational design of multi-epitope, string-of-beads constructs. Because epitope assembly creates novel junctional peptides, the platform evaluates each junction for proteasomal processing, MHC presentation, and immunogenicity. It then optimizes epitope order and spacer selection to minimize unintended immune responses while preserving therapeutic focus. ### What is the output of myCONSTRUCT? myCONSTRUCT returns several independently optimized candidate designs rather than a single construct, reducing reliance on any one sequence. Each candidate can be assessed for the intended human context and relevant preclinical species, including mouse. The workflow can also begin from an existing construct and optimize its epitope order and spacers. ### What is the turnaround time for myCONSTRUCT? String-of-beads design optimization with myCONSTRUCT has a turnaround time of one week. ## myRNA Page: https://www.myneotx.com/solutions/myrna ### What is myRNA? myRNA is a codon optimization engine for therapeutic mRNA. It balances codon usage against RNA structural stability while handling locked regulatory regions, multiple open reading frames, degradation hotspots, restriction sites, unwanted motifs, stem-size control, and modified nucleotides. ### How does myRNA differ from a standard codon optimizer? A standard codon optimizer works only on the nucleotide sequence. myRNA optimizes multiple coding sequences within a single RNA as one interdependent molecule, accepts a defined codon usage bias, preserves locked regions such as UTRs and linkers, and avoids degradation hotspots, unwanted motifs, and oversized stems. ### What is the turnaround time for myRNA? Codon optimization with myRNA has a turnaround time of one week. ## Pipeline, assets, and partnerships Page: https://www.myneotx.com/assets ### What is the myNEO antigen target library? The myNEO antigen target library contains MHC-bound and surface antigen targets identified and prioritized across a range of cancer indications. These targets are [available for licensing](https://www.myneotx.com/contact) to biologics, vaccine, and T-cell therapy developers. ### Which cancer indications does myNEO's target discovery cover? myNEO's target discovery currently covers colorectal, bladder, breast, pancreatic, liver, cervical, and head and neck cancers, as well as glioblastoma. ### What internal programs is myNEO developing? As of August 2026, myNEO's lead program is [MNE-C261](https://www.myneotx.com/assets/mne-c261), an off-the-shelf mRNA vaccine targeting [camyotopes](https://www.myneotx.com/platform/camyotopes) in microsatellite-stable colorectal cancer. The program is in preclinical development, with clinical initiation targeted for Q4 2027. The pipeline also lists MNE-CXX2, MNE-CXX3, and the personalized MNE-P201 program. ### What partnered programs use myNEO's technology? myNEO's technology is used in a Phase I personalized DNA program with the University of Liverpool for patients with non-small cell lung cancer. Two additional personalized programs are at the preclinical stage with undisclosed European and US partners targeting solid tumors. ### What partnership opportunities does myNEO offer? myNEO discusses target licensing, strategic collaborations, co-development, and use of its technologies within [partner programs](https://www.myneotx.com/contact). Commercial structures, exclusivity, territory, and access models are agreed for each opportunity. ## MNE-C261 Page: https://www.myneotx.com/assets/mne-c261 ### What is MNE-C261? MNE-C261 is myNEO's lead internal program: an off-the-shelf mRNA-LNP vaccine targeting [camyotopes](https://www.myneotx.com/platform/camyotopes) in microsatellite-stable colorectal cancer (MSS-CRC). The design includes 26 CRC-specific camyotope targets. ### What is the development status of MNE-C261? As of August 2026, MNE-C261 is in preclinical development. myNEO is working toward initiation of a first Phase I/IIa trial, with clinical initiation targeted for Q4 2027. ### What preclinical characteristics are reported for MNE-C261? Reported preclinical characteristics for the program include strong polyfunctional immunogenicity, target abundance up to 99%, population coverage of more than 95%, and broad HLA coverage of more than 95%. ## Publications Page: https://www.myneotx.com/publications ### What is neoMS? [neoMS](https://www.myneotx.com/publication/mill-neoms-mhc-epitope-presentation-2022) is myNEO's HLA-agnostic MHC epitope presentation prediction algorithm. It uses a transformer-based attention architecture trained on 386,647 epitopes to model the antigen-processing pathway, including proteasomal cleavage, TAP transport, MHC binding, and presentation. ### What is neoIM? neoIM is myNEO's immunogenicity prediction algorithm. It predicts whether an epitope will activate T cells. In [published retrospective analyses](https://www.myneotx.com/publication/pfitzer-accelerating-neoantigen-discovery-2025), neoIM achieved up to 30% higher precision than existing predictors and identified up to 50% more clinically actionable neoantigens. ### What types of publications does myNEO provide? myNEO publishes peer-reviewed [scientific papers](https://www.myneotx.com/publications#scientific-papers), [technology papers](https://www.myneotx.com/publications#technology-papers) describing individual solutions, and [whitepapers](https://www.myneotx.com/publications#whitepapers) covering neoantigen discovery, immunogenicity prediction, cancer vaccines, camyotopes, and computational immunology. ## Careers Page: https://www.myneotx.com/careers ### Are there open positions at myNEO Therapeutics? There are currently no open positions at myNEO Therapeutics. New opportunities will be announced on the careers page when available. myNEO also welcomes spontaneous applications, and candidates can send a cover letter and resume to [hr@myneotx.com](mailto:hr@myneotx.com). ### Does myNEO accept spontaneous applications? Yes. myNEO welcomes spontaneous applications. Candidates can send a cover letter and resume to [hr@myneotx.com](mailto:hr@myneotx.com). The company offers a hands-on startup culture with close collaboration, open communication, personal growth, and direct involvement in decisions. ## Contact and confidentiality Page: https://www.myneotx.com/contact ### How can organizations contact myNEO? Organizations can use the contact form or email [info@myneotx.com](mailto:info@myneotx.com) to discuss platform questions, solution fit, partnerships, licensing, demonstrations, or proposals. ### Will my sequences and data stay confidential? Yes. Projects operate under confidentiality terms agreed in advance. On hosted platforms, access is tenant-based so each customer's data remains isolated, with sign-in through Amazon Cognito and multi-factor authentication. ### What information can I submit through the contact form? The contact form accepts a name, email address, company, and message. Do not submit confidential or proprietary information through the website. The [Terms of Use](https://www.myneotx.com/legal/terms-of-use) state that myNEO is not obligated to treat website submissions as confidential. Confidential discussions are handled under a separate agreement. ## Privacy and website data Page: https://www.myneotx.com/legal/privacy-statement ### How does myNEO use website data and cookies? myNEO may process information to respond to inquiries, analyze and improve its website and services, send relevant communications, and personalize experiences. The consent-based analytics and tracking tools in use are listed in the [Privacy Statement](https://www.myneotx.com/legal/privacy-statement), and form inputs are masked in session replay. ### How can privacy questions be submitted? Privacy questions or concerns can be sent to [dpo@myneotx.com](mailto:dpo@myneotx.com). General inquiries can be sent to [info@myneotx.com](mailto:info@myneotx.com), and questions about website terms can be sent to [legal@myneotx.com](mailto:legal@myneotx.com).